United Therapeutics (UTHR)
(Real Time Quote from BATS)
$275.79 USD
+0.60 (0.22%)
Updated May 22, 2024 12:02 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 501 - 520 ( 589 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2012 Financials Beat And Double Digit Growth Intact. Near- Term Focus Remains On March 31st PDUFA For Oral Treprostinil. Reiterate OUTPERFORM & $91 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Preview: We Believe Consensus Is Achievable, But Focus Is On March 31st PDUFA For Oral Treprostinil
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Pulling A Rabbit Out Of Its Hat: FDA Accepts Rapid Resubmission Of Oral Treprostinil NDA With Class 1 Review And March 31 PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Revenues And Earnings Beat (Again) And We Project Consistent Double Digit Growth Through 2016. Reiterate OUTPERFORM and $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Preview: We Believe Street Estimates Are Achievable;
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Oral Treprostinil Receives CRL Instead of Approval; We Recommend Buying On Weakness; Reiterate OUTPERFORM And $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of October 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
We Believe Self-Injected Treprostinil Could Be Important For Life-Cycle Management;
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
September and Remaining 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2:12 Revenues And Earnings Beat (Again; 2012 Revenue Guidance Reconfirmed-Reiterate OUTPERFORM and $91Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L